Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-07-29
2011-11-29
Lundgren, Jeffrey S (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08067430
ABSTRACT:
A method of treating HIV infection by using the novel anti-HIV activity of the opioid antagonist naloxone.
REFERENCES:
patent: 4546103 (1985-10-01), Huebner
patent: 4888346 (1989-12-01), Bihari et al.
patent: 2003/0069263 (2003-04-01), Breder et al.
patent: 2003/0105121 (2003-06-01), Bihari
De Clercq, Eric. “New Developments in anti-HIV chemotherapy”. Biochimica et Biophysica Acta. 2002. vol. 1587. pp. 258-275.
Schmidt, William K. “Alvimopan (ADL 8-2698) is a Novel Peripheral Opioid Antagonist”. The American Journal of Surgery. 2001. vol. 182, Suppl to Nov. 2001). pp. 27S-38S.
Suzuki et al, Methadone induces CCR5 and promotes AIDS virus infection, FEBS Letters, 519 , 2002, pp. 173-177.
Medicine.net (Definition of HTLV-III, retrieved from the internet on May 14, 2010, HTML: http://www.medterms.com/script/main/art.asp?articlekey=38558.
Schafer et al. Drug Discovery Today 2008, 13 (21/22), 913-916.
Horig et al. Journal of Translational Medicine 2004, 2(44).
Ando et al.(Remington: The science and practice of pharmacy, 20th Edition, pp. 704-712).
Gekker, Ganya et al., Naltrexone Potentiates Anti-HIV-1 Activity of Antiretroviral Drugs in CD4+ Lymphocyte Cultures, Drug and Alcohol Dependence, 2001, 257-263, vol. 64.
Ho, Wen-Zhe et al., Methylnaltrexone Antagonizes Opioid-Mediated Enhancement of HIV Infection, The Journal of Pharmacology and Exp. Therapeutics, 2003, 1158-1162, 307(3).
Gekker, G. et al. Jun. 2002. “Naloxone Potentiates Anti-HIV-1 Activity of Antiretroviral Drugs in CD4+ Lymphocyte Cultures.” International Journal of Infectious Diseases. vol. 6. Suppl. 2. pp. S14-S15.
Gekker, G. et al. Jan. 2001. “Naltrexone Potentiates Anti-HIV-1 Activity of Antiretroviral Drugs in CD4+ Lymphocyte Cultures.” Drug and Alcohol Dependence. vol. 64. pp. 257-263.
Brown et al. 2009. “Low-Dose Naltrexone for Disease Prevention and Quality of Life.” Medical Hypotheses. vol. 72. No. 3. pp. 333-337.
Wang et al. 2007. “Diffrerent Effects of Opioid Antagonists on Mu-, Delta-, and Kappa-Opioid Receptors With and Without Agonist Pretreatment.” The Journal of Pharmacology and Experimental Therapeutics. vol. 321. No. 2. pp. 544-552.
Peng et al. 2007. “Pharmacological Properties of Bivalent Ligands Containing Butorphan Linked to Nalbuphine, Naltrexone, and Naloxone at Mu, Delta, and Kappa Opioid Receptors.” J. Med. Chem. vol. 50. pp. 2254-2258.
Cao Chuanhai
Nyland Susan B.
Specter Steven
Ugen Kenneth E.
Lawson Michele L.
Lundgren Jeffrey S
Rao Savitha
Smith & Hopen , P.A.
University of South Florida
LandOfFree
Anti-HIV activity of the opioid antagonist naloxone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-HIV activity of the opioid antagonist naloxone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-HIV activity of the opioid antagonist naloxone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4305696